Correction: Bushen-Yizhi formula ameliorates cognitive dysfunction through SIRT1/ER stress pathway in SAMP8 mice

PDF  |  How to cite

Oncotarget. 2020; 11:2684-2685. https://doi.org/10.18632/oncotarget.27505

Metrics: PDF 980 views  |   ?  

Shi-Jie Zhang1,*, Ting-Ting Xu1,*, Lin Li1, Yu-Min Xu1, Zi-Ling Qu1, Xin-Chen Wang1, Shui-Qing Huang1, Yi Luo1, Na-Chuan Luo1, Ping Lu1, Ya-Fei Shi1, Xin Yang2 and Qi Wang1

1 Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2 Department of Pharmacy, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
* These authors contributed equally to this work

Published: July 07, 2020

This article has been corrected: While reviewing the database for this study, the authors discovered that the Tunel staining data for all 6 panels in Figure 4C did not represent the relevant group. The corrected Figure 4, obtained using original data, is given below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:49338–49350. DOI: https://doi.org/10.18632/oncotarget.17638.

Figure 4: BSYZ protects against apoptosis in both hippocampus and cortex. Western blot analysis of Bax, Bcl-2 and Caspase-3 in hippocampus (A) and cortex (B). (C) TUNEL staining in parietal cortex in mice. Scale bar: 50 μm. BSYZ-L: Bushen-Yizhi (1.46 g/kg/d); BSYZ-M: Bushen-Yizhi (2.92 g/kg/d); BSYZ-H: Bushen-Yizhi (5.84 g/kg/d); DON: donepezil. Data represent mean ± SEM (n = 20 per group). #P < 0.05, ###P < 0.001 vs. SAMR1; *P < 0.05, **P < 0.01, ***P < 0.001 vs. SAMP8.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27505